Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Dietary omega-6 lipids promote postinjury aberrant bone formation in obesity
Stefanie L. Moye, Monisha Mittal, Tarun Srinivasan, Sneha Korlakunta, Chase A. Pagani, Ayelet Dar, Oromo Geshow, Dylan Feist, Lauren G. Zacharias, Zhao Li, Aaron W. James, Gerta Hoxhaj, Andrew M. Smith, Katherine A. Gallagher, Thomas P. Mathews, Robert J. Tower, Benjamin Levi
Stefanie L. Moye, Monisha Mittal, Tarun Srinivasan, Sneha Korlakunta, Chase A. Pagani, Ayelet Dar, Oromo Geshow, Dylan Feist, Lauren G. Zacharias, Zhao Li, Aaron W. James, Gerta Hoxhaj, Andrew M. Smith, Katherine A. Gallagher, Thomas P. Mathews, Robert J. Tower, Benjamin Levi
View: Text | PDF
Research Article Bone biology Inflammation Metabolism

Dietary omega-6 lipids promote postinjury aberrant bone formation in obesity

  • Text
  • PDF
Abstract

Obesity is associated with impaired wound healing, but the mechanisms linking excess adiposity to aberrant tissue repair remain unresolved. Heterotopic ossification (HO) is a severe example of pathologic tissue repair in which mesenchymal progenitor cells (MPCs) undergo aberrant osteochondral differentiation within soft tissue, leading to joint contractures and pain. Here, we show that accumulation of dietary omega-6 (ω-6) lipids in the injury site is a key mechanism linking obesity to HO. Specifically, in mice fed a high-fat diet (HFD), injured tissues were enriched in linoleic and arachidonic acids, providing substrate for myeloid COX-2–dependent prostaglandin E2 (PGE2) production. PGE2 then drove a transcriptional program in MPCs that promoted osteochondral differentiation. An isocaloric, low linoleic acid HFD reduced HO despite comparable obesity, demonstrating that dietary lipid composition, rather than adiposity alone, drove pathological repair. Clinical data mirrored these findings, showing that obesity conferred increased HO risk, and COX-2 inhibition reduced HO exclusively in obese patients. Together, these findings identify injury site ω-6 lipid enrichment as the key signal linking the diet to MPC reprogramming, pointing to dietary lipid modulation as an actionable strategy to limit HO in obesity.

Authors

Stefanie L. Moye, Monisha Mittal, Tarun Srinivasan, Sneha Korlakunta, Chase A. Pagani, Ayelet Dar, Oromo Geshow, Dylan Feist, Lauren G. Zacharias, Zhao Li, Aaron W. James, Gerta Hoxhaj, Andrew M. Smith, Katherine A. Gallagher, Thomas P. Mathews, Robert J. Tower, Benjamin Levi

×

Figure 4

Myeloid COX-2 promotes local PGE2 production and HO in obesity.

Options: View larger image (or click on image) Download as PowerPoint
Myeloid COX-2 promotes local PGE2 production and HO in obesity.
(A) Over...
(A) Overview: dietary LA from an HFD serves as a precursor for AA, which is metabolized by COX enzymes into prostaglandins, including PGE2. (B–D) COX-2 and PGE2 levels at the HO site and serum PGE2 levels in HFD and control mice (day 3 after B/T; n = 5 mice/group). (E) Schematic of scRNA-seq workflow for HO-site tissue before and after B/T injury. (F) UMAP of HO-site cell populations annotated by canonical marker expression. (G and H) Ptgs1 and Ptgs2 expression by cell type and within myeloid cells split by diet and injury status. (I) Schematic of CD11b+ myeloid cell enrichment. (J) Ptgs2 expression in CD11b+ myeloid and CD11b– nonmyeloid cells (n = 4–5 mice/group). (K and L) Confocal imaging and quantification of COX-2 colocalization with CD11b+ myeloid cells in injured hind limbs at 1 week after B/T (n = 3–4 mice/group). Each point represents the proportion of CD11b+ cells expressing COX-2 within individual fields of view. White arrows denote Cox2+ CD11b+ myeloid cells. Scale bars: 1,000 μm (×10), 100 μm (×20), 50 μm (×63). (M) Schematic for 1-week celecoxib or vehicle treatment. (N) HO-site PGE2 levels in control, control + celecoxib, HFD, and HFD + celecoxib mice (day 3 after B/T; n = 5 mice/group). (O) Heatmap of chemokine and cytokine expression at day 3 after B/T. Control and HFD data from Figure 2B were reanalyzed with celecoxib-treated groups for comparison (n = 8–10 mice/group). (P and Q) μCT images and HO quantification (9 weeks after B/T; n = 6–8 mice/group). Statistics: Mann-Whitney test (B–D and L) or 1-way ANOVA (J, N, and Q). Data represent at least 2 independent experiments. Means ± SEM are plotted. *P < 0.05; **P < 0.01; ***P < 0.001. See also Supplemental Figure 5.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts